Connect your AI

NovoCure NVCR Payments, Tax Related to Net Settlement on Equity Awards

Payments, Tax Related to Net Settlement on Equity Awards at other companies

TKO Group HoldingsTKO

$8.09M—

Lennox InternationalLII

$10.5M-7.1%

Ryan Specialty HoldingsRYAN

$1.71M+9.2%

Amylyx Pharmaceuticals, Inc.AMLX

$3.94M+345%

Nutanix, Inc.NTNX

$32.38M-50.0%

Roivant SciencesROIV

$7.78M—

Other financials

Income statement

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

Market cap$1.64B-36.7%

Enterprise value$1.59B-36.3%

P/S2.4×-1.7×

Profitability

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept nvcr:PaymentsTaxRelatedToNetSettlementOnEquityAwards.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's payments, tax related to net settlement on equity awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is NovoCure's payments, tax related to net settlement on equity awards?: NovoCure (NVCR) reported payments, tax related to net settlement on equity awards of $556K in Q1 2026.
What does payments, tax related to net settlement on equity awards mean?: Captures cash outflows associated with the tax withholding obligations settled by the company on behalf of employees during equity award vesting. This occurs when the company withholds a portion of shares to cover statutory tax requirements, effectively paying the tax authority in cash. It is a critical metric for understanding the cash impact of share-based compensation programs on shareholder dilution and liquidity.